Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan;96(1):e29365.
doi: 10.1002/jmv.29365.

Durability of humoral and cellular immunity six months after the BNT162b2 bivalent booster

Julien Favresse  1   2 , Constant Gillot  1 , Mélanie Closset  3 , Julien Cabo  2 , Loris Wauthier  2 , Clara David  4 , Marc Elsen  2 , Jean-Michel Dogné  1 , Jonathan Douxfils  1   4   5
Affiliations

Durability of humoral and cellular immunity six months after the BNT162b2 bivalent booster

Julien Favresse et al. J Med Virol. 2024 Jan.

Abstract

Studies about the duration of the humoral and cellular response following the bivalent booster administration are still scarce. We aimed at assessing the humoral and cellular response in a cohort of healthcare workers that received this booster. Blood samples were collected before the administration of the bivalent booster from Pfizer-BioNTech and after 14, 28, 90, and 180 days. Neutralizing antibodies against either the D614G strain, the delta variant, the BA.5 variant, or the XBB.1.5 subvariant were measured. The cellular response was assessed by measurement of the release of interferon gamma from T cells in response to an in vitro SARS-CoV-2 stimulation. A substantial waning of neutralizing antibodies was observed after 6 months (23.1-fold decrease), especially considering the XBB.1.5 subvariant. The estimated T1/2 of neutralizing antibodies was 16.1 days (95% CI = 10.2-38.4 days). Although most participants still present a robust cellular response after 6 months (i.e., 95%), a significant decrease was also observed compared to the peak response (0.95 vs. 0.41 UI/L, p = 0.0083). A significant waning of the humoral and cellular response was observed after 6 months. These data can also help competent national authorities in their recommendation regarding the administration of an additional booster.

Keywords: BA.5; SARS-CoV-2; XBB.1.5; bivalent booster; cellular response; humoral response; omicron.

PubMed Disclaimer

References

REFERENCES

    1. Seekircher L, Bánki Z, Kimpel J, et al. Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial. Lancet Microbe. 2023;4:e612-e621.
    1. Nilles EJ, Paulino CT, De St Aubin M, et al. Tracking immune correlates of protection for emerging SARS-CoV-2 variants. Lancet Infect Dis. 2023;23(2):153-154.
    1. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205-1211.
    1. Carr EJ, Wu MY, Gahir J, et al. Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous omicron infection. Lancet Infect Dis. 2023;23(7):781-784.
    1. Wherry EJ, Barouch DH. T cell immunity to COVID-19 vaccines. Science. 2022;377(6608):821-822.

LinkOut - more resources